$XBI $128.63 -1.44%
Covid Updates
$BNTX -6.7% & $PFE -2.2% Pfizer and BioNTech Submit Request to Amend U.S. FDA Emergency Use Authorization of Their COVID-19 Vaccine Booster to Include All Individuals 18 and Older source
$MRNA -3.2% Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age source
$INO +4.6% INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S. source
Pipeline Updates
$FNCH +5.7% Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection source
$GNFT +3.7% GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program source
$TERN -5.5% TERNS REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 1 PROOF OF CONCEPT CLINICAL TRIAL OF THR-Β AGONIST TERN-501 source
$INCY 0.0% OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis source
$IOVA -0.8% Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting source
$ZYME 0.0% Zymeworks Launches Global Phase 3 Zanidatamab Trial In First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA) source
$ALDX +1.5% Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance source
$STTK -28.6% SHATTUCK LABS ANNOUNCES PRELIMINARY CLINICAL DATA FROM ONGOING PHASE 1 CLINICAL TRIALS OF ARC FUSION PROTEINS SL-172154 AND SL-279252 source
$HZNP -0.5% Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis source
$EXEL -1.7% Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer source
$IMTX -13.9% Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME source
$IMCR -2.1% Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting source
$ONCR -4.1% ONCORUS ANNOUNCES DETAILS OF UPCOMING ONCR-177 PHASE 1 INITIAL CLINICAL DATA PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER’S (SITC) 2021 ANNUAL MEETING source
$RAIN +3.0% Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Milademetan source
$ARAV -1.0% Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting source
$PSTV -2.2% PLUS THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR 186RNL TARGETED RADIOTHERAPEUTIC FOR LEPTOMENINGEAL METASTASES source
$UBX +8.9% UNITY BIOTECHNOLOGY ANNOUNCES IMPROVEMENT IN VISUAL ACUITY SUSTAINED THROUGH 24 WEEKS FOLLOWING SINGLE DOSE OF UBX1325 IN PHASE 1 STUDY OF PATIENTS WITH ADVANCED VASCULAR EYE DISEASE source
$ALXO -21.5% ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpacept Showing Emerging Clinical Benefit in Survival-Based Endpoints in Patients with Advanced Solid Tumors source
$CMPS -16.4% COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression source
Financial Updates
$MRTX +5.0% Mirati Therapeutics Announces Proposed Public Offering of Common Stock source
Posted by JM
ความคิดเห็น